Ras-Mek-Erk Signaling Regulates Nf1 Heterozygous Neointima Formation  by Stansfield, Brian K. et al.
The American Journal of Pathology, Vol. 184, No. 1, January 2014ajp.amjpathol.orgSHORT COMMUNICATION
Ras-Mek-Erk Signaling Regulates Nf1 Heterozygous
Neointima Formation
Brian K. Stansﬁeld,*y Waylan K. Bessler,*y Raghuveer Mali,*y Julie A. Mund,*y Brandon D. Downing,*y Reuben Kapur,*yz and
David A. Ingram, Jr.*yzFrom the Herman B. Wells Center for Pediatric Research* and the Departments of Pediatrics and Neonatal-Perinatal Mediciney and Biochemistry and




David A. Ingram, Jr, M.D.,
Herman B. Wells Center for
Pediatric Research, Indiana
University School of Medicine,
1044 W Walnut St, R4/470,
Indianapolis, IN 46202. E-mail:
dingram@iu.edu.opyright ª 2014 American Society for Inve
ublished by Elsevier Inc. All rights reserved
ttp://dx.doi.org/10.1016/j.ajpath.2013.09.022Neuroﬁbromatosis type 1 (NF1) results from mutations in the NF1 tumor-suppressor gene, which en-
codes neuroﬁbromin, a negative regulator of diverse Ras signaling cascades. Arterial stenosis is a
nonneoplastic manifestation of NF1 that predisposes some patients to debilitating morbidity and
sudden death. Recent murine studies demonstrate that Nf1 heterozygosity (Nf1þ/) in monocytes/
macrophages signiﬁcantly enhances intimal proliferation after arterial injury. However, the downstream
Ras effector pathway responsible for this phenotype is unknown. Based on in vitro assays demonstrating
enhanced extracellular signal-related kinase (Erk) signaling in Nf1þ/ macrophages and vascular
smooth muscle cells and in vivo evidence of Erk ampliﬁcation without alteration of phosphatidylinositol
3-kinase signaling in Nf1þ/ neointimas, we tested the hypothesis that Ras-Erk signaling regulates
intimal proliferation in a murine model of NF1 arterial stenosis. By using a well-established in vivo
model of inﬂammatory cell migration and standard cell culture, neuroﬁbromin-deﬁcient macrophages
demonstrate enhanced sensitivity to growth factor stimulation in vivo and in vitro, which is signiﬁcantly
diminished in the presence of PD0325901, a speciﬁc inhibitor of Ras-Erk signaling in phase 2 clinical
trials for cancer. After carotid artery injury, Nf1þ/ mice demonstrated increased intimal proliferation
compared with wild-type mice. Daily administration of PD0325901 signiﬁcantly reduced Nf1þ/ neo-
intima formation to levels of wild-type mice. These studies identify the Ras-Erk pathway in
neuroﬁbromin-deﬁcient macrophages as the aberrant pathway responsible for enhanced neointima
formation. (Am J Pathol 2014, 184: 79e85; http://dx.doi.org/10.1016/j.ajpath.2013.09.022)Supported by Pediatric Scientist Development Program (National Insti-
tute of Child Health and Human Development) grant K12HD000850
(B.K.S.) and NIH grants P50 NS052606 (D.A.I.) and TLI RR025759
(B.D.D., and A. Shakhar, P.I.).Neuroﬁbromatosis type 1 (NF1) results from mutations in
the NF1 tumor-suppressor gene, which encodes the protein
neuroﬁbromin. Neuroﬁbromin negatively regulates Ras ac-
tivity in multiple cell types by accelerating the hydrolysis of
active Ras-GTP to its inactive diphosphate conformation.1
These loss-of-function mutations accelerate Ras signaling
and sensitize vessel wall cells and circulating hematopoietic
cells, particularly myeloid progenitors and their differenti-
ated progeny, to growth factors implicated in maintaining
vascular wall homeostasis and disease pathogenesis.1e4
Some patients with NF1 are predisposed to intimal prolif-
eration, termed neointima, leading to debilitating arterial
stenosis and tissue ischemia that contribute signiﬁcantly to
the premature mortality observed in this population.5
Nf1 heterozygous (Nf1þ/) mice display increased neo-
intima formation, characterized by proliferating vascularstigative Pathology.
.smooth muscle cells (VSMCs) and inﬁltration of bone
marrowederived macrophages after arterial ligation, which is
reminiscent of patients with NF1.5,6 Neuroﬁbromin-deﬁcient
endothelial cells, VSMCs, and bone marrowederived
myeloid cells demonstrate preferential activation of the Ras-
Erk signaling pathway, without corresponding alterations in
Rasephosphatidylinositol 3-kinase signaling, in response to
multiple growth factors in vitro.2e4,7 This is an interesting
observation because lineage-restricted inactivation of a sin-
gle Nf1 gene in endothelial cells and/or VSMCs does not
replicate the striking neointima observed inNf1 heterozygous
Stansﬁeld et almice. However, we recently demonstrated that lineage-
speciﬁc inactivation of a single Nf1 gene copy in monocytes/
macrophages is sufﬁcient to reproduce the enhanced neointima
formation observed in Nf1 heterozygous mice compared with
wild-type (WT) mice.8
Based on these observations, we used in vitro and in vivo
systems of macrophage function to test the hypothesis that
Nf1 heterozygous macrophage function and mobilization to
sites of inﬂammation are directly controlled by Ras-Erk
signaling and that use of a speciﬁc and long-acting inhibi-
tor of Ras-Erk signaling, under evaluation in multiple phase
1 and 2 clinical trials for cancer and preclinical models of




Protocols were approved by the Institutional Animal Care
and Use Committee at Indiana University (Indianapolis, IN).
Nf1þ/ mice were obtained from Tyler Jacks, Ph.D.,
(Massachusetts Institute of Technology, Cambridge, MA)
and backcrossed 13 generations into the C57BL/6J strain.
Mice were genotyped by PCR, as previously described.2
Nf1þ/ and WT mice (C57BL/6J) were crossed to
generate experimental progeny. Male mice, between 12 and
15 weeks of age, were used for experiments.
Carotid Artery Ligation
In ﬁve independent experiments, the carotid arteries of Nf1þ/
and WT mice were mechanically injured via ligation of the
right common carotid artery proximal to the bifurcation, as
previously described.2,8 Brieﬂy, experimental and control
animals were anesthetized by inhalation of a 2% isoﬂurane
and 98% oxygen admixture. Under a dissecting micro-
scope, the proximal arterial tree was exposed through a
midline neck incision and the right common carotid artery
was ligated using a 6-0 silk suture. The contralateral carotid
artery was sham ligated as a control. Buprenorphine, 15 mg
(Reckitt, Richmond, VA), was administered via i.p. injec-
tion and mice recovered for 28 days without complication.
Mitogen-Activated Protein Kinase/Erk Kinase (Mek)
Inhibitor Administration
Nf1þ/ and WT mice were administered 5 or 10 mg
PD0325901/kg once daily via oral gavage. Treatment
commenced 7 days before arterial injury and continued until
tissue was harvested 28 days after arterial ligation. In some
experiments, treatment was initiated 7 days after arterial
injury and continued through tissue harvest at 28 days after
injury. Nf1þ/ and WT control mice were administered
an equivalent volume of hydroxypropylmethylcellulose
(Sigma-Aldrich, St. Louis, MO) as a vehicle control.80Histopathological Characteristics and Morphometric
Analysis
After a 28-day recovery period, mice were anesthetized via
inhalation of a 2% isoﬂurane and 98% oxygen admixture.
Carotid arteries were perfusion ﬁxed in situ with 10 mL of
0.125 mmol/L adenosine plus 0.0125 mmol/L sodium
nitroprusside for 10 minutes, followed by Z-ﬁx solution
(Anatech, Battle Creek, MI), as previously described.2,8 By
using a dissecting microscope, whole injured and uninjured
control carotid arteries were excised, incubated in Z-ﬁx
solution at 4C for 24 hours, and parafﬁn embedded. On
identiﬁcation of the carotid bifurcation, serial arterial cross
sections (7 mm thick) were collected at 200-mm intervals
across the length of the artery. Van Gieson staining was
performed according to standard methods, and arterial cross
sections at 400, 800, and 1200 mm proximal to the ligation
were analyzed for neointima formation using ImageJ soft-
ware version 1.46 (NIH, Bethesda, MD). For each cross
section, lumen area, area inside the internal elastic lamina
(IEL), and area inside the external elastic lamina (EEL) were
measured. To quantify neointima area, intima area (IEL
area  lumen area), media area (EEL area  IEL area), and
in tima/media (I/M) ratio (intima area/media area) were
calculated and reported. Arteries containing signiﬁcant
thrombus (>50% lumen occlusion) at 400 mm were
excluded from analysis. Numbers of excluded mice did not
differ signiﬁcantly according to genotype and/or treatment
group.
Macrophage Recruitment In Vivo
Nf1þ/ and WT mice were challenged with 100 mg lipo-
polysaccharide (LPS) or PBS by i.p. injection. In separate
experiments, mice were sacriﬁced at 24, 48, 72, and 96
hours after LPS challenge, and peritoneal cells were
collected via peritoneal lavage in 5 mL of PBS. Lavage ﬂuid
and cells were incubated in red cell lysis buffer for 10 mi-
nutes, followed by inactivation with 1 mL of adult bovine
serum (ABS). Samples were centrifuged and resuspended in
500 mL of 10% ABS in Dulbecco’s modiﬁed Eagle’s me-
dium. The total number of lavage cells was determined
using a hemocytometer. Cells were then incubated on ice
with murine Fc Blocking Reagent (Miltenyi Biotec, Co-
logne, Germany) for 10 minutes before staining with
CD115-phosphatidylethanolamine (eBioscience, San Diego,
CA), F4/80-Allophycocyanin (Serotech, Oxford, UK),
TER119-Pac Blue (eBioscience), and LIVE/DEAD violet
ﬁxable dead cell stain (Invitrogen, Grand Island, NY) for 30
minutes and resuspended in 2% ABS in PBS. Stained
samples were acquired on a BD LSRII ﬂow cytometer (BD
Biosciences, San Jose, CA) equipped with a 405-nm violet
laser, a 488-nm blue laser, and a 633-nm red laser. At least
100,000 events were collected for samples. Data were
collected uncompensated and analyzed using FlowJo soft-
ware, version 8.7.3 (Tree Star, Ashland, OR). Monocyte andajp.amjpathol.org - The American Journal of Pathology
Erk Signaling Mediates Arterial Stenosismacrophage cell numbers were calculated as the product of
CD115 or F4/80 as a percentage of live cells and the total
lavage cell count and reported as cells/mL of lavage volume.
In some experiments, mice were administered 5 mg
PD0325901/kg per day via oral gavage beginning 7 days
before LPS injection and continued until peritoneal lavage
was performed at 96 hours.
Isolation of BM-Derived Macrophages
Bone marrow (BM)ederived macrophages were generated
from long bones of 8- to 12-week-old WT and Nf1þ/ mice.
Brieﬂy, BM cells were ﬂushed into a 50-mL falcon tube
using a syringe needle and Iscove’s modiﬁed Dulbecco’s
medium (IMDM). Cells were collected by centrifugation at
800  g for 5 minutes (Beckman Coulter, Brea, CA) at
room temperature, and red blood cells were lysed with red
cell lysis buffer for 5 minutes at room temperature. The cells
were centrifuged and resuspended in 5 mL IMDM. Low-
density BM cells were isolated by density-gradient centri-
fugation using Histopaque 1083 (Sigma-Aldrich). For
macrophages, low-density BM cells were cultured in com-
plete media consisting of IMDM, 20% fetal bovine serum
supplemented with 1% penicillin/streptomycin, and 100 ng/
mL macrophage colony-stimulating factor (M-CSF; Pepro-
Tech, Rocky Hill, NJ). Cells were used for experiments
between three and six passages.
Macrophage Proliferation Assay
Cells were starved in media containing 0.2% bovine serum
albumin (BSA) in IMDM without growth factors for 6 to 7
hours. A total of 5  104 macrophages were placed in a 96-
well plate in 200 mL starvation media in the presence or
absence of the indicated concentration of M-CSF. Cells
were serum starved for 48 hours and pulsed with 1.0 mCi
(0.037 MBq) [3H] thymidine for 6 hours. Cells were har-
vested using an automated 96-well cell harvester (Brandel,
Gaithersburg, MD), and thymidine incorporation was
determined as cpm. Where indicated, cells were pretreated
with the indicated concentration of PD0325901 or vehicle
for 1 hour.
Macrophage Migration Assay
The bottom of Transwell ﬁlters (8-mmol/L pore ﬁlter;
Corning, Tewksbury, MA) was coated with 20 mg/mL
ﬁbronectin CH296 peptide for 2 hours at 37C and rinsed
twice with PBS containing 2% BSA. The ﬁbronectin CH296
peptideecoated ﬁlters were placed in the lower chamber
containing 500 mL complete medium, with or without 100
ng/mL M-CSF. A total of 2.5  105 macrophages were
resuspended in 100 mL IMDM and allowed to migrate to-
ward the bottom of the top chamber. After 20 hours of in-
cubation at 37C, nonmigrated cells in the upper chamber
were removed with a cotton swab. The migrated cells thatThe American Journal of Pathology - ajp.amjpathol.orgattached to the bottom surface of the membrane were stained
with 0.1% crystal violet dissolved in 0.1 mol/L borate, pH
9.0, and 2% ethanol for 5 minutes at room temperature. The
number of migrated cells per membrane was determined in
ﬁve random ﬁelds with an inverted microscope using a 20
objective lens. Where indicated, cells were pretreated with
the indicated concentration of PD0325901 or vehicle for
1 hour.Macrophage Adhesion Assay
Flat-bottom, 96-well polystyrene plates (BD Biosciences)
were coated with 20 mg/mL ﬁbronectin fragment CH296 in
PBS for 1 hour at 37C. Wells were washed once with PBS,
incubated with 20 mg/mL BSA for 1 hour at 37C to block
non-speciﬁc sites, and again washed twice with PBS. For
examination of cell adhesion on the coated surface, 1  105
cells were added to each well and incubated at 37C for
60 minutes. At the end of the incubation, unbound cells
were removed by aspiration and wells were washed twice
with cold PBS. Adherent cells were ﬁxed with 3.5% form-
aldehyde and stained with 0.1% crystal violet. The stain was
eluted with 10% acetic acid, and absorbance was determined
at 600 nm using a microplate reader (Spectramax 250;
Molecular Devices, Sunnyvale, CA). Where indicated, cells
were pretreated with the indicated concentration of
PD0325901 or vehicle for 1 hour.Western Blot Analysis
Peritoneal cells from Nf1þ/ and WT mice treated with either
PD0325901 or vehicle control were harvested via peritoneal
lavage at 96 hours after stimulation with 100 mg LPS. Cells
were lysed in lysis buffer, and equal amounts of protein
lysates were fractionated on a 4% to 20% SDS-PAGE
gel. The separated protein was electrophoretically trans-
ferred onto a nitrocellulose membrane, and Western blot
analysis was performed using antiephosphorlyated-Erk and
anti-Erk antibodies (Cell Signaling, Beverly, MA). Sepa-
rately, BM-derived macrophages from WT and NF1þ/
mice were isolated and starved overnight in serum- and
growth factorefree medium and stimulated with 100 ng/mL
M-CSF for 5 minutes in the presence or absence of
PD0325901. Cells were harvested and lysed, as described,
and Western blot analysis was performed using antie
phosphorlyated-Erk and anti-Erk antibodies.Statistical Analysis
All values are presented as means  SEM. Intima area and
I/M ratio analysis for each treatment group were assessed
by one-way analysis of variance with a Tukey’s post
hoc test using GraphPad Prism, version 6.0b (GraphPad
Software, San Diego, CA). P < 0.05 was considered
signiﬁcant.81
Figure 1 Ras-Erk signaling regulates neuroﬁbromin-deﬁcient and WT
macrophage function in vivo. A: Total cell count from the peritoneum of WT
and Nf1þ/ at 96 hours after i.p. injection of 100 mg LPS. Data represent
means SEM cell count per mL (nZ 4 to 5). B: Recruitment ofWT and Nf1þ/
macrophages to the peritoneum after i.p. injection of 100 mg LPS over 96
hours. Data represent means  SEM cell count per mL (n Z 4 to 5).
C: Recruitment of WT and Nf1þ/ monocytes and macrophages to the peri-
toneum at 96 hours after i.p. injection of 100 mg LPS in the presence or
absence of PD0325901. Data represent means SEM cell count per mL (nZ
5). D: Erk activity in LPS-elicited peritoneal macrophages isolated from WT
and Nf1þ/ mice administered daily 5 mg PD0325901/kg or placebo.
Western blot analyses for Erk phosphorylation and total Erk are shown.
Quantitative densitometry  SEM is reported as a ratio for phosphorylated-
Erk density/total-Erk density. The data are from a single experiment and
represent a replicate of three total experiments. *P < 0.001 for WT versus
Nf1þ/ macrophages; **P < 0.001 for LPS-stimulated WT and Nf1þ/ total
cell count versus placebo-stimulated WT and Nf1þ/ total cell counts; yP <
0.01 for LPS-stimulated WT and Nf1þ/ monocytes and macrophages versus
LPS-stimulated WT and Nf1þ/ monocytes and macrophages in the presence
of PD0325901; zP < 0.001 for LPS-stimulated WT versus LPS-stimulated
Nf1þ/ monocytes and macrophages; and zzP < 0.001 for LPS-stimulated
WT and Nf1þ/ monocytes and macrophages versus placebo-stimulated WT
and Nf1þ/ monocytes and macrophages.
Figure 2 PD0325901 inhibits neuroﬁbromin-deﬁcient and WT macro-
phage function in vitro. WT and Nf1þ/ macrophage proliferation (A) and
migration (B) in response to M-CSF in the presence of PD0325901, where
indicated. C: Adhesion to ﬁbronectin in the presence of PD0325901, where
indicated. A: Data represent thymidine incorporation reported as means 
SEM cpm (n Z 6). B: Data represent average  SEM number of migrated
cells per high-power ﬁeld (nZ 6). C: Data represent means  SEM optical
density (n Z 5). D: Erk activity in WT and Nf1þ/ cultured macrophages
stimulated with M-CSF in the presence or absence of 100 nmol/L
PD0325901. Western blots for Erk phosphorylation and total Erk are shown.
Quantitative densitometry  SEM is reported as a ratio for phosphorylated-
Erk density/total-Erk density. The data are from a single experiment and
represent a replicate of three other experiments. Black bars, Nf1þ/; white
bars, WT. *P < 0.001 for WT macrophages stimulated with M-CSF versus
Nf1þ/ macrophages stimulated with M-CSF; yP < 0.001 for WT and Nf1þ/
macrophages stimulated with M-CSF versus WT and Nf1þ/ macrophages
stimulated with M-CSF in the presence of PD0325901; zP < 0.001 for WT
macrophages stimulated with PBS versus Nf1þ/ macrophages stimulated
with PBS; xP < 0.001 for WT and Nf1þ/ macrophages stimulated with PBS
versus WT and Nf1þ/ macrophages stimulated with M-CSF; {P < 0.001 for
WT versus Nf1þ/ macrophages; and kP < 0.001 for WT and Nf1þ/ mac-
rophages versus WT and Nf1þ/ macrophages in the presence of
PD0325901.
Stansﬁeld et alResults
Ras-Mek-Erk Signaling Regulates Neuroﬁbromin-
Deﬁcient and WT Macrophage Function
To assess monocyte and macrophage response to growth
factors associated with arterial disease, we used a well-
established model of LPS-induced peritonitis in Nf1þ/ and
WT mice. After i.p. injection of 100 mg LPS, Nf1 hetero-
zygous mice more readily mobilized hematopoietic cells to
the peritoneum at 96 hours when compared with WT mice
(Figure 1A). Analysis of the lavage demonstrated a more
robust recruitment of CD115-positive monocytes and F4/
80-positive macrophages to the peritoneum of Nf1þ/ mice,
compared with WT mice (Figure 1, B and C). The prefer-
ential mobilization of Nf1þ/ monocytes and macrophages
was effectively suppressed with daily administration of
PD0325901 (Figure 1C), a speciﬁc and potent inhibitor of82Ras-Erk signaling1 (Figure 1D). Not surprisingly, recruit-
ment of WT monocytes and macrophages was suppressed
by PD0325901, thus demonstrating that the Ras-Erk
signaling pathway regulates the recruitment of monocytes/
macrophages to sites of inﬂammation in nonmutant animals.
To assess the regulatory role of Ras-Erk signaling in
macrophage function, cultured macrophages were stimu-
lated with M-CSF, a growth factor implicated in cardio-
vascular disease and arterial stenosis,13 in the presence or
absence of PD0325901. Neuroﬁbromin-deﬁcient macro-
phages demonstrated increased proliferation, migration, and
adhesion in response to single growth factor stimulation via
Ras-Erk activation when compared with WT macrophages
(Figure 2, AeD), which is consistent with previous re-
ports.2,8 In the presence of nanomolar concentrations of
PD0325901, Nf1þ/ macrophage function was signiﬁcantly
reduced to levels of WT macrophages in vitro (Figure 2,
AeC). WT macrophages also demonstrated an impaired
response to M-CSF in the presence of PD0325901; how-
ever, this response was modest when compared with Nf1þ/
macrophages (Figure 2, AeC).ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Daily administration of PD0325901 prevents neointima for-
mation in Nf1þ/ mice after arterial injury. A: Representative photomi-
crographs of Van Giesonestained carotid arteries from WT and Nf1þ/ mice
28 days after no injury, injury, and placebo treatment or injury and 5 or 10
mg PD0325901/kg per day treatment. Arrows indicate neointima bound-
aries; boxes, the area of injured artery that is magniﬁed below. Scale barZ
100 mm. Quantiﬁcation of neointima area (B) and I/M ratio (C) of unin-
jured and injured carotid arteries from WT and Nf1þ/ mice treated with
either placebo or PD0325901. Data represent the means  SEM neointima
area of three arterial cross sections (400, 800, and 1200 mm proximal to the
ligation) (nZ 12 to 15). *P < 0.01 for WT and Nf1þ/ uninjured versus WT
and Nf1þ/ injured with placebo treatment; yP < 0.01 for WT injured with
placebo treatment versus Nf1þ/ injured with placebo treatment; and zP <
0.01 for WT and Nf1þ/ injured with placebo treatment versus WT and
Nf1þ/ injured with 5 or 10 mg PD0325901/kg per day treatment.
Figure 4 Initiation of Mek inhibition after arterial injury reduces
neointima formation in Nf1þ/ mice. A: Representative photomicrographs
of Van Giesonestained carotid arteries from WT and Nf1þ/ mice 28 days
after injury and placebo treatment or injury and 5 mg PD0325901/kg per
day treatment. Arrows indicate neointima boundaries; boxes, area of
injured artery that is magniﬁed to the right. Scale bar Z 100 mm. Quan-
tiﬁcation of neointima area (B) and I/M ratio (C) of uninjured and injured
carotid arteries from WT and Nf1þ/ mice treated with either placebo or
PD0325901. Data represent the means  SEM neointima area of three
arterial cross sections (400, 800, and 1200 mm proximal to the ligation)
(nZ 8 to 10). *P< 0.01 for WT and Nf1þ/ uninjured versus WT and Nf1þ/
injured with placebo treatment; yP < 0.01 for WT injured with placebo
treatment versus Nf1þ/ injured with placebo treatment; zP < 0.01 for WT
and Nf1þ/ injured with placebo treatment versus WT and Nf1þ/ injured
with PD0325901 treatment. D: Representative photomicrograph of injured
carotid artery cross section from placebo and PD0325901-treated Nf1þ/
mice stained with anti-Mac3 antibody (brown) and counterstained with
hematoxylin (blue). Arrows indicate neointima boundaries; arrowheads,
positive Mac3 staining; box, the area of injured artery that is magniﬁed to
the right. Scale bar Z 100 mm.
Erk Signaling Mediates Arterial StenosisDaily Administration of PD0325901 Prevents
Neointima Formation in Nf1þ/ Mice after Arterial
Injury
To assess the role of Ras-Erk signaling in Nf1þ/ and WT
neointima formation, Nf1þ/ and WT mice were adminis-
tered daily oral 5 or 10 mg PD0325901/kg per day for 1
week before arterial injury; this was continued until arteries
were harvested. This dose range effectively inhibits down-
stream Ras-Mek-Erk signaling for 24 hours in multiple bone
marrow lineages, as demonstrated in several animal
models.1,10 After arterial ligation of the right common ca-
rotid artery, Nf1þ/ mice demonstrated enhanced neointima
formation when compared with WT mice, which is
consistent with previous ﬁndings2,6,8 (Figure 3, AeC).
Daily administration of PD0325901 signiﬁcantly reduced
Nf1þ/ neointima formation in a dose-dependent manner,
returning arterial stenosis and remodeling to levels observed
in WT mice. Consistent with previous in vitro and in vivoThe American Journal of Pathology - ajp.amjpathol.orgobservations that Erk signaling is preferentially activated in
neuroﬁbromin-deﬁcient myeloid cells, vascular wall cells,
and neointimas,1,10,14 Nf1þ/ neointimas expressed similar
phosphorylated-AKT staining when compared with WT
neointimas, regardless of treatment group, thus demon-
strating the speciﬁcity of PD0325901 (data not shown). The
observation that PD0325901 moderately reduced neointima
formation in WT mice suggests Ras-Mek-Erk signaling
maintains the vascular wall in unperturbed states and reg-
ulates the response of the vascular wall to injury. Recent
reports using a murine model of myeloproliferative
dysplasia have demonstrated that PD0325901 partially
corrects aberrant myelopoiesis and ineffective erythropoi-
esis observed in this model.1,10 However, examination of
the bone marrow from Nf1þ/ and WT mice in each treat-
ment group did not differ in cellularity or myeloid/erythroid83
Stansﬁeld et alratio, signifying that the reduction of neointima size
observed in each treatment group is more likely due to ef-
fects on differentiated macrophage function outside the bone
marrow compartment, rather than through alterations in
developmental hematopoiesis (data not shown).
Initiation of Mek Inhibition after Arterial Injury
Reduces Neointima Formation in Nf1þ/ Mice
To test whether inhibition of the Mek-Erk signaling axis is
efﬁcacious in reducing neointima formation after arterial
remodeling has been initiated, Nf1þ/ and WT mice were
administered either daily 5 mg PD0325901/kg or vehicle,
commencing on day 7 after arterial injury and continuing
through day 28 after injury. Morphometric analysis of
injured and control arteries from Nf1þ/ and WT mice
demonstrated that initiation of treatment 7 days after arterial
injury signiﬁcantly reduced neointima area and I/M ratio in
Nf1þ/ and WT mice when compared with vehicle-treated
mice (Figure 4, AeC). Although neointima formation in
both Nf1þ/ and WT mice was slightly increased in the
vehicle-treatment group, reduction of Nf1þ/ and WT neo-
intima formation was greater when treatment was initiated
after arterial injury. In addition, Nf1þ/ neointimas from
mice administered PD0325901 demonstrated fewer inﬁl-
trating macrophages when compared with vehicle-treated
mice (Figure 4D).Discussion
Mounting evidence suggests that Ras signaling partially reg-
ulates vascular wall homeostasis and that perturbation in Ras
signaling results in a variety of congenital and acquired car-
diovascular disease manifestations.15,16 Recent animal studies
demonstrate that ampliﬁcation of Ras signaling enhances
neointima formation, whereas inhibition of the canonical Ras-
Mek-Erk pathway reduces neointima formation and VSMC
proliferation and migration in vivo.15,17 Neuroﬁbromin, the
protein product of the NF1 gene, accelerates the hydrolysis of
Ras-GTP to its inactive conformation to negatively regulate
Ras signaling. Thus, even partial loss of neuroﬁbromin
expression leads to Ras acceleration and increased cell pro-
liferation and accumulation in both unperturbed and diseased
states. In support of this hypothesis, arterial cross sections from
neuroﬁbromin-deﬁcient mice express increased Erk signaling
within the neointima layer, compared with WT controls. The
signaling is effectively restored with early administration of
imatinib mesylate, an inhibitor of multiple signaling pathways,
including the platelet-derived growth factor-BB receptor, after
arterial injury.6
Macrophages are early and important cellular effectors of
cardiovascular remodeling and neointima formation.13,18,19
Macrophages secrete growth factors and matrix metal-
loproteinases that stimulate vascular smooth muscle cell
proliferation and migration, and are implicated in84cardiovascular disease pathogenesis.13,19 Although macro-
phages comprise a small percentage of the total cell mass
within Nf1þ/ and WT neointimas, neuroﬁbromin-deﬁcient
macrophages signiﬁcantly exaggerate the proliferative
response of Nf1þ/ and WT VSMCs via the Ras-Mek-Erk
signaling cascade when compared with WT macrophages.2
These previous observations support our recent report
demonstrating that heterozygous inactivation of the Nf1
gene in monocytes/macrophages alone completely repro-
duced the neointima phenotype observed in Nf1þ/ mice.8
Herein, we show that neuroﬁbromin-deﬁcient monocytes
and macrophages are hypersensitive to inﬂammatory states
and growth factor stimulation, which is mediated via the
Ras-Mek-Erk signaling axis. Furthermore, we show that daily
administration of PD0325901 to speciﬁcally inhibit Ras-
Mek-Erk signaling signiﬁcantly reduced Nf1þ/ neointimas
in a dose-dependent manner and resulted in a modest reduc-
tion of WT neointimas. Administration of PD0325901 at 1
week after arterial injury further reduced neointima formation
inNf1þ/ andWTmice, indicating a therapeutic windowmay
exist. PD0325901 is a next-generation Mek inhibitor and has
been used as an experimental therapeutic agent in preclinical
testing for multiple NF1-related manifestations and several
phase 1 and 2 clinical trials for cancer.9,11,12 In particular,
PD0325901 has shown signiﬁcant efﬁcacy in preclinical
models of juvenile myelomonocytic leukemia, a common
malignancy associated with Ras mutations in myeloid pro-
genitor cells.1,10 Thus, Ras-Erk signaling in neuroﬁbromin-
deﬁcient monocytes/macrophages may be an important
molecular target for the development of novel therapeutics to
prevent or treat NF1 vasculopathy.References
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